Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

FSD Pharma Inc C.HUGE

Alternate Symbol(s):  HUGE

FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.


CSE:HUGE - Post by User

Post by Bigmac4000on Jun 19, 2020 9:07am
122 Views
Post# 31168518

FSD Debt

FSD DebtExactly, this pumper is absolutely horrible at his job. By making comments like "zero debt" they are just calling out to be corrected. In which case yourself and others are forced to correct them and remind new investors of FSD debt and bad decisions! I did some of my own Google reading on FDA phases and scheduling. I don't know what possessed FSD to get into this PEA drug with so little time left on the patent. It's barely going to make it to market and be replaced with generic. The costs alone are astronomical and out of 5000 drugs in trials only 5 make it. Another thing with this pumper and others is their claim that just because FSD has the right to use the $100,000,000 dilution doesn't mean they will. Well you said when FSD mentioned a RS they wouldn't until it was good for the investors with institutional money. Do you recall the 201 RS at almost delisted value destroying the stock and infuriating the little guy. This company does what it wants with no regard for investors. They will use this 100,000,000 like their own piggybank. Please keep in mind from 2018 till today FSD raised around 53 million and blew through it. Then raised 4.50 million internally and blew through it, then sold Hightide, cannara shares for around 8.4 million combined and blew through around 3+ million of that so far. That's around 65.9 million dollars raised and wasted around 61 million so far in two years. Feel for to nickel and dime my math. I'm pretty darn close. 61 million wasted dollars and in that time they made approximately $310,000 counting rent and the massive massive $260,000 on weed sales. 61 million in 2 years gone. Now another 100,000,000 of play money along with a 10,000,000 dilution stock sale with a buy back at $9+ a share I believe. Go brag about that! "RE:RE:RE:FSD Pharma 100,000,000$ Prospectus All true Milman and BM There is debt, but it requires reading and understanding financials which the promoters dont seem to do For example on the F10: Use of proceeds , from the shelf offering is to- Repayment of Prismic Debt Total debt of $1,900,000 less $150,000 converted to Class B Shares during Q2 2020 And on page 22 In this section describing the Debt Securities, the terms "Corporation" and "FSD Pharma" refer only to FSD Pharma Inc. without any of its subsidiaries. This section describes the general terms that will apply to any Debt Securities issued pursuant to this Prospectus. The specific terms of the Debt Securities, and the extent to which the general terms described in this section apply to those Debt Securities, will be set forth in the applicable Prospectus Supplement. The Debt Securities will be issued in one or more series under an indenture (the "Indenture") to be entered into between FSD Pharma and one or more trustees (the "Trustee") that will be named in a Prospectus Supplement for a series of Debt Securitiy Debt now and debt planned Promoters play with words, but dont read or understand numbers Realists do. Facts matter"
<< Previous
Bullboard Posts
Next >>